References
- 1
Bender W, Albus M, Möller HJ, Tretter F.
Towards systemic theories in biological psychiatry.
Pharmacopsychiatry.
2006;
39
((Suppl 1))
4-9
- 2
Dursun SM.
5-HT2 receptors, hallucinations, and dementia.
Br J Psychiatry.
1992;
161
719
- 3
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar K-A.
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double blind,
cross-over study in healthy volunteers.
Pharmacopsychiatry.
2005;
38
301-311
- 4
Manford M, Andermann F.
Complex visual hallucinations. Clinical and neurobiological insights.
Brain.
1998;
121
(( Pt 10))
1819-1840
- 5
Mylecharane EJ.
5-HT2 receptor antagonists and migraine therapy.
J Neurol.
1991;
238
((Suppl 1))
S45-S52
- 6
Norton JW, Corbett JJ.
Visual perceptual abnormalities: hallucinations and illusions.
Semin Neurol.
2000;
20
111-121
- 7
Pelak VS, Liu GT.
Visual hallucinations.
Curr Treat Options Neurol.
2004;
6
75-83
- 8
Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M.
Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for
treating LSD-induced hallucinogenesis.
Psychopharmacology.
1989;
98
495-499
- 9
Siddiqui Z, Ramaswamy S, Petty F.
Mirtazapine for Charles Bonnet syndrome.
Can J Psychiatry.
2004;
49
787-788
Correspondence
D. KoetheM.D.
Department of Psychiatry and Psychotherapy
University of Cologne
Kerpener Str. 62
50924 Cologne
Germany
Phone: +49/221/478 86 23 1
Fax: +49/221/478 87 20 0
Email: koethe@ecnp.net
